Should nonalcoholic fatty liver disease be renamed?

Digestive Diseases

Volumn 23, Issue 1, 2005, Pages 72-82

  Loria, Paola ^a,c   Lonardo, Amedeo ^b   Carulli, Nicola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UO Medicina Interna e Gastroenterologia Ospedale Civile di Modena   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Definitions; Fibrosis; Hepatic steatosis; Insulin resistance; Leptin; Metabolic syndrome; NASH; Pathogenesis

Indexed keywords

LEPTIN; LIPID; TRIACYLGLYCEROL;

ALCOHOL LIVER CIRRHOSIS; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; FATTY LIVER; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIVER CIRRHOSIS; MEDICAL LITERATURE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LEPTIN; RISK FACTORS; TERMINOLOGY;

EID: 20444467246     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084728     Document Type: Review

References (140)

1. Lonardo A, Loria P, Carulli N: Insulin resistance in non-alcoholic fatty liver disease; in Leuschner U, James O, Dancygier H (eds): Steatohepatitis (NASH and ASH). Dordrecht, Kluwer, 2001, pp 104-113.
2. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP: Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-597.
3. Day C, Saksena SJ: Non-alcoholic steatohepatitis: Definitions and pathogenesis. J Gastroenterol Hepatol 2002;17(suppl 3):S377-S384.
4. Ludwig J, Viggiano T, McGill D, Ott B: Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
5. Diehl A, Goodman Z, Ishak K: Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-1062.
6. Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B: Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
7. Matteoni C, Younossi Z, Gramlich T, Bopari N, Liu Y, McCullough A: Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
8. Sanyal AJ: American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-1725.
9. Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
10. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ: Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
11. Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.
12. Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, Ohba K, Isomoto H, Mizuta Y, Hayashida K, Murase K, Kadota T, Murata I, Kohno S: Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002;17:1098-1105.
13. Loria P, Lonardo A, Lombardini S, Leonardi F, Carulli L, Ganazzi D, Rudilosso A, Verrone AM, Ricchi M, Carulli N: Epidemiologia e storia naturale delle epatopatia steatosica nonalcolica. Ann Ital Med Int 2003;18:15S-31S.
14. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M: Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999;94:3010-3014.
15. Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G: The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999;34:85-91.
16. Byron D, Minuk GY: Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 1999;24:813-815.
17. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ: Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669.
18. Caldwell SH, Hespenheide EE: Subacute liver failure in obese women. Am J Gastroenterol 2002;97:2058-2062.
19. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-1354.
20. Bugianesi E, Leone N, Vanni E, Marckesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M: Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
21. Sorensen HT, Mellemkjaer L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, Vilstrup H: Risk of cancer in patients hospitalised with fatty liver: A Danish cohort study. J Clin Gastroenterol 2003;36:356-359.
22. Perry LT, Wannamethee SG, Shaper AG: Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998;21:732-737.
23. Okamoto M, Takeda Y, Yoda Y, Kobayashi K, Fujino MA, Yamagata Z: The association of fatty liver and diabetes risk. J Epidemiol 2003;13:15-21.
24. Clouston AD, Powell EE: Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol 2002;16:767-781.
25. Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone AM, Borsatti A, Bertolotti M, Cassani F, Bagni A, Muratori P, Gavazzi D, Bianchi FB, Carulli N: Non organ specific autoantibodies in nonalcoholic fatty liver disease. Prevalence and correlates. Dig Dis Sci 2003;48:2173-2181.
26. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH: Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996;62:1802-1805.
27. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N: Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7:797-801.
28. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ: Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-373.
29. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM: Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998;2:292-298.
30. Zamboni F, Franchello A, David E, Rocca G, Ricchiuti A, Lavezzo B, Pizzetto M, Salizzoni M: Effect of macrovescicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant 2001;15:53-57.
31. Selzner M, Clavien PA: Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001;21:105-113.
32. Carulli N, Loria P: Epatopatie croniche: da criptogenetiche a multifattoriali. Ann Ital Med Int 2003;18:57-59.
33. Zelman S: The liver in obesity. Arch Intern Med 1958;90:141-156.
34. Creutzfeld W, Frerichs H, Sickinger K: Liver disease and diabetes mellitus. Prog Liver Dis 1970;13:371-407.
35. Bastie A, Capron JP: Etiologies of a moderate and prolonged elevation of serum activity of transaminases: the end of 'transaminitis'? Gastroenterol Clin Biol 1993;17:33-36.
36. Brunt EM: Nonalcoholic steatohepatitis. Semin Liver Dis 2004;24:3-20.
37. Dixon JB, O'Brien PE, Bhathal PS: Letter. Gastroenterology 2002;122:841-842.
38. Farrell GC: Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 2003;18:124-138.
39. Neuschwander-Tetri BA, Caldwell SH: Non-alcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 2003;37:1202-1219.
40. Thaler H: Die Fettleber und ihre pathogenetische Beziehung zur Leberzirrhose. Virchows Arch Pathol Anat Physiol Klin Med 1962;335:180-210.
41. Batman PA, Scheuer PJ: Diabetic hepatitis precedingthe onset of glucose intolerance. Histopathology 1985;9:237-243.
42. Baker AL: Nonalcoholic steatonecrosis: A unique histopathologic lesion of the liver with multiple causes. Surv Dig Dis 1985;3:154-164.
43. French SW, Eidus LB, Freeman J: Nonalcoholic fatty hepatitis: An important clinical condition. Can J Gastroenterol 1989;3:189-197.
44. Wanless I, Lentz J: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-1110.
45. Lonardo A, Bellini M, Tondelli E, Frazzoni M, Grisendi A, Pulvirenti M, Della Casa G: Non-alcoholic steatohepatitis and the 'bright liver syndrome': Should a recently expanded clinical entity be further expanded? Am J Gastroenterol 1995;90:2072-2074.
46. Lonardo A: Is non-alcoholic steatohepatitis another facet of the bright liver syndrome? (letter). Ital J Gastroenterol 1996;28:187.
47. Lonardo A: La sindrome del fegato iperecogeno. Argomenti Gastroenterol Clin 1997;10:77-89.
48. Kral J, Schaffner F, Pierson R, Wang J: Body fat topography as an independent predictor of fatty liver. Metabolism 1993;42:548-551.
49. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G: Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000;45:1929-1934.
50. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
51. Marchesini G, Forlani G: NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002;35:497-499.
52. Day CP: Non-alcoholic steatohepatitis (NASH): Where are we now and where are we going? Gut 2002;50:585-588.
53. Hoyumpa AM, Jr, Greene HL, Dunn GD, Schenker S: Fatty liver: Biochemical and clinical considerations. Am J Dig Dis 1975;20: 1142-1150.
54. Garg A, Misra A: Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab 2002;87:3019-3022.
55. Longo R, Ricci C, Masutti F, Vidimari R, Croce LS, Bereich L, Tiribelli C, Dalla Palma L: Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993;28:297-302.
56. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-3028.
57. Powell E, Cooksley W, Hanson R, Searle J, Halliday J, Powell L: The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
58. Abdelmalek M, Ludwig J, Lindor KD: Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995;20:127-130.
59. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC: Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25:108-111.
60. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, Naveau S: Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-638.
61. Lonardo A: Fatty liver and non-alcoholic steatohepatitis: Where do we stand and where are we going ? Dig Dis 1999;17:80-89.
62. Ferrannini E: The metabolic syndrome; in Mogensen CE (ed): Target Organ Damage in the Mature Hypertensive. London, Science Press, 1993, pp 2.31-2.49.
63. Moller DE, Flier JS: Insulin resistance - mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-948.
64. Meigs JB: Epidemiology of the metabolic syndrome. Am J Manag Care 2002;8:S283-S292.
65. Unger RH: Lipid overload and overflow: Metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003;14:398-403.
66. Unger RH: Minireview: Weapons of lean body mass destruction: The role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:5159-5165.
67. Neel JV: Diabetes mellitus: A 'thrifty' genotype rendered detrimental by 'progress'? Bull World Health Organ 1999;77:694-703; discussion 692-693.
68. Unger RH: Lipotoxic diseases. Annu Rev Med 2002;53:319-336.
69. Unger RH, Zhou YT, Orci L: Regulation of fatty acid homeostasis in cells: Novel role of leptin. Proc Natl Acad Sci LISA 1999;96:2327-2332.
70. Schaffer JE: Lipotoxicity: When tissues over-eat. Curr Opin Lipidol 2003;14:281-287.
71. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K: Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000;95:3584-3589.
72. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, Liddle C, Samarasinghe D, George J: Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? Hepatology 2002;36:403-409.
73. Cortez-Pinto H, Camilo M, Baptista A, De-Oliveira A, DeMoura M: Non-alcoholic fatty liver: Another feature of the metabolic syndrome? Clin Nutr 1999;18:353-358.
74. Tankurt E, Biberoglu S, Ellidokuz E, Hekimsoy Z, Akpinar H, Comlekci A, Okan A, Sagol O: Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis (letter). J Hepatol 1999;31:963.
75. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
76. Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N, Lurie Y, Bass DD: Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 1999;92:73-79.
77. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN: Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
78. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA: Ninety patients with nonalcoholic steatohepatitis: Insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-2961.
79. Marchesini G, Brizi M, Blanchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
80. Comert B, Mas MR, Erdem H, Dinc A, Saglamkaya U, Cigerim M, Kuzhan O, Unal T, Kocabalkan F: Insulin resistance in non-alcoholic steatohepatitis. Dig Liver Dis 2001;33:353-358.
81. Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone AM, Bagni A, Bertolotti M, Ganazzi D, Carulli N: Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis 2002;34:204-211.
82. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, Gorge J: NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379.
83. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002;35:367-372.
84. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923.
85. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-916.
86. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, Antonimi TM, Alessandri C: Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 2003;18:588-594.
87. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
88. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, Caro JF: Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1349-1355.
89. Luyckx F, Sheen A, Desaive C, Dewe W, Gielen J, Lefebvre P: Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diabetes Metab 1998;24:355-361.
90. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-1517.
91. Crespo J, Fernandez-Gil P, Hernandez-Guerra M, Cayon A, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F: Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? Obes Surg 2001;11:254-257.
92. Zimmerman HJ, MacMurray FG, Rappaport H, Alpert LK, Washington DC: Studies of the liver in diabetes mellitus. J Lab Clin Med 1950;36:912-921.
93. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L: Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: Role of insulin resistance. Gut 2004;53:1020-1023.
94. Lonardo A, Bellini M, Tartoni P, Tondelli E: The bright liver syndrome: Prevalence and determinants of a 'bright' liver echopattern. Ital J Gastroenterol Hepatol 1997;29:351-356.
95. Ruhl CE, Everhart JE: Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-79.
96. Czaja AJ: Recurrence of nonalcoholic steatohepatitis after liver transplantation. Liver Transpl Surg 1997;3:185-186.
97. Angelico F, Del Ben M, Francioso S, Hurtova M, Battista S, Palmieri GP, Tisone G, Angelico M: Recurrence of insulin resistant metabolic syndrome following liver transplantation. Eur J Gastroenterol Hepatol 2003;15:99-102.
98. Andersen T, Gluud C, Franzmann MB, Christoffersen P: Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-229.
99. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A: Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994;125:239-241.
100. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107.
101. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, Rubino A: Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997;42:1428-1432.
102. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR: Orlistat in the treatment of NASH: A case series. Am J Gastroenterol 2003;98:926-930.
103. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-419.
104. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE: Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647-1654.
105. Coyle WJ, Delaney N, Yoshihashi A, Lawson P: Metformin treatment in patients with non-alcoholic steatohepatitis normalizes LFTs and improves histology (abstract). Gastroenterology 1999;116:1198-1199.
106. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N: Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-894.
107. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
108. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-1017.
109. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K: Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-544.
110. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-196.
111. Marchesini G, Marzocchi R, Natale S: NAFLD - Why not to treat the insulin resistance? Proceedings of the European Association for the Study of the Liver. Monothematic Conference: 'Non-alcoholic steatohepatitis: from cell biology to clinical practice'. Estoril, Sept 2004.
112. Wang RT, Koretz RL, Yee HF Jr: Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003;115:554-559.
113. Sanyal AJ: Insulin resistance and nonalcoholic steatohepatitis: Fat or fiction? Am J Gastroenterol 2001;96:274-276.
114. Neuschwander-Tetri BA: A resistance movement in NASH. Am J Gastroenterol 2001;96:2813-2814.
115. Li Z, Clark J, Diehl AM: The liver in obesity and type 2 diabetes mellitus. Clin Liver Dis 2002;6:867-877.
116. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
117. Itoh S, Yougel T, Kawagoe K: Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987;82:650-654.
118. Lee RG: Nonalcoholic steatohepatitis: A study of 49 patients. Hum Pathol 1989;20:594-598.
119. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994;107:1103-1109.
120. Teli MR, James OF, Burt AD, Bennett MK, Day CP: The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995;22:1714-1719.
121. Propst A, Propst T, Judmaier G, Vogel W: Prognosis in nonalcoholic steatohepatitis (letter). Gastroenterology 1995;108:1607.
122. Cortez-Pinto H, Baptista A, Camilo M, Valente A, Saragoca A, Carneiro De Moura M: Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalised patients. Dig Dis Sci 1996;41:172-179.
123. Angulo P, Keach J, Batts K, Lindor K: Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999;30:1356-1362.
124. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T: Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123.
125. Chitturi S, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, Samarasinghe D, Lin R, Abeygunasekera S, George J: HFE mutations, hepatic iron, and fibrosis: Ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002;36:142-149.
126. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292.
127. Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR: Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 2003;138:1240-1244.
128. Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N: Nonalcoholic steatohepatitis: Risk factors for liver fibrosis. Hepatol Res 2002;24:429-438.
129. Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR: Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 2003;138:1240-1244.
130. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M: Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179-187.
131. Loria P, Lonardo A, Carulli N: Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver (letter). Hepatology 2004;39:1748.
132. Lombardini S, Loria P, Lonardo A, D'Amico R, Verrone AM, Leonardi F, Carulli L, Bagni A, Bertolotti M, Borsatti A, Ganazzi D, Carulli N: Progression of nonalcoholic fatty liver disease (NAFLD) associates with increased insulin resistance (abstract). Dig Liver Dis 2003;35:17A.
133. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR: Nonalcoholic steatohepatitis: Histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004;35:1070-1082.
134. Koruk M, Savas MC, Yilmaz O, Taysi S, Karakok M, Gundogdu C, Yilmaz A: Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis.J Clin Gastroenterol 2003;37:177-182.
135. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study. Circulation 2004;102:42-47.
136. Heathcote J: Weighty issues in hepatitis C. Gut 2002;51:7-8.
137. Boden G: Pathogenesis of type 2 diabetes. Insulin resistance. Endocrinol Metab Clin North Am 2001;30:801-815.
138. Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R: Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004;27:2057-2066.
139. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004;279:32345-32353.
140. Reaven G: The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33:283-303.